Onconetix Inc (ONCO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Onconetix Inc (ONCO) has a cash flow conversion efficiency ratio of -0.181x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.12 Million) by net assets ($11.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Onconetix Inc (ONCO) net asset quality to measure how much of total assets are equity-financed.
Onconetix Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Onconetix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Onconetix Inc (ONCO) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Onconetix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Onconetix Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ausmon Resources Ltd
AU:AOA
|
-0.232x |
|
PHAXIAM Therapeutics S.A.
PA:PHXM
|
-0.540x |
|
Schroder European Reit Plc
LSE:SERE
|
0.022x |
|
Gentlemens Equity S.A.
PA:MLGEQ
|
N/A |
|
BioNeutra Global Corp
V:BGA
|
-0.004x |
|
Profusa, Inc. Common Stock
NASDAQ:PFSA
|
0.091x |
|
Maven Income and Growth VCT 4 PLC
LSE:MAV4
|
-0.007x |
|
Tres Or Resources Ltd
V:TRS
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Onconetix Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Onconetix Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see ONCO market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $15.77 Million | $-9.68 Million | -0.614x | +43.79% |
| 2024-12-31 | $9.61 Million | $-10.50 Million | -1.092x | +88.71% |
| 2023-12-31 | $1.40 Million | $-13.58 Million | -9.670x | -2395.38% |
| 2022-12-31 | $22.39 Million | $-8.68 Million | -0.388x | +72.58% |
| 2021-12-31 | $1.45 Million | $-2.04 Million | -1.413x | -286.65% |
| 2020-12-31 | $4.73 Million | $-1.73 Million | -0.365x | -165.70% |
| 2019-12-31 | $6.00 Million | $-825.13K | -0.138x | -- |
About Onconetix Inc
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other … Read more